Find the Right Market Report
Search thousands of industry reports, market insights, and research studies in one place.
Search thousands of industry reports, market insights, and research studies in one place.
Date : 11 February 2026
| Company | Description |
| Charles River Laboratories | This usually explores a complete set of cardiotoxicity screening services through its Safety Pharmacology & Discovery Services divisions. |
| Labcorp/Covance | Its offerings include in vitro & in-vivo cardiovascular safety, biomarkers, and specialized testing. |
| Eurofins Scientific | Their portfolio assists regulatory compliance (FDA/ICH) and early-stage drug discovery. |
| WuXi AppTec | This facilitates ion channel assessments, stem cell-derived cardiomyocyte platforms, and specialized imaging techniques. |
| Evotec | Its offering comprises integration of human-relevant cell models with advanced analytical technologies. |
| ICON plc | This has explored a "one-stop shop" solution, which combines clinical pharmacology units (CPUs) with an experienced cardiac safety core lab. |
| Certara | A firm emphasizes in silico modeling, simulation, and predictive analytics. |
| Simulations Plus | This provides in silico tools and services for cardiotoxicity screening, especially through its ADMET Predictor & GastroPlus platforms. |
| Axion BioSystems | Its offering focuses on its Maestro multielectrode array (MEA) platform. |
| Multi-Channel Systems (MCS) | This explores the entire set of electrophysiology tools for in vitro and in vivo cardiotoxicity screening. |
The global cardiotoxicity screening market size was estimated at USD 3.21 billion in 2025 and is predicted to increase from USD 3.59 billion in 2026 to approximately USD 9.61 billion by 2035, expanding at a CAGR of 11.58% from 2026 to 2035.
Your one-stop hub for detailed Cardiotoxicity Screening Market stats and analysis: Access the Dashboard
Speak with a healthcare analyst about your research, consulting, or platform needs.